Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function

Wenwei Hu*, Cen Zhang*, Rui Wu†, Yvonne Sun‡, Arnold Levine*,b,1, and Zhaohui Feng*†

*Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08903; and †Institute for Advanced Study, Princeton, NJ 08540

Contributed by Arnold J. Levine, January 28, 2010 (sent for review November 30, 2009)

Whereas cell cycle arrest, apoptosis, and senescence are traditionally thought of as the major functions of the tumor suppressor p53, recent studies revealed two unique functions for this protein: p53 regulates cellular energy metabolism and antioxidant defense mechanisms. Here, we identify glutaminase 2 (GLS2) as a previously uncharacterized p53 target gene to mediate these two functions of the p53 protein. GLS2 encodes a mitochondrial glutaminase catalyzing the hydrolysis of glutamine to glutamate. p53 increases the GLS2 expression under both nonstressed and stressed conditions. GLS2 regulates cellular energy metabolism by increasing production of glutamate and α-ketoglutarate, which in turn result in enhanced mitochondrial respiration and ATP generation. Furthermore, GLS2 regulates antioxidant defense function in cells by increasing reduced glutathione (GSH) levels and decreasing ROS levels, which in turn protects cells from oxidative stress (e.g., H2O2)-induced apoptosis. Consistent with these functions of GLS2, the activation of p53 increases the levels of glutamate and α-ketoglutarate, mitochondrial respiration rate, and GSH levels and decreases reactive oxygen species (ROS) levels in cells. Furthermore, GLS2 expression is lost or greatly decreased in hepatocellular carcinomas and the overexpression of GLS2 greatly reduced tumor cell colony formation. These results demonstrated that as a unique p53 target gene, GLS2 is a mediator of p53’s role in energy metabolism and antioxidant defense, which can contribute to its role in tumor suppression.

Results

The Human GLS2 Gene Contains a p53 Consensus DNA-Binding Element. As a transcription factor, p53 binds to the p53 consensus DNA-binding elements in its target genes to regulate their transcription (14). By employing a p53 MH algorithm, a computer program scanning for potential p53 target genes by identifying the potential p53 consensus DNA-binding elements (15), we have recently identified several unique p53 target genes (16–18). Employing this algorithm, the human GLS2 gene was identified as a potential p53 target gene containing three potential p53 consensus DNA-binding elements in its promoter region and intron 1 (Fig. 14).

GLS2 encodes a mitochondrial glutaminase (~65 kDa) that catalyzes the hydrolysis of glutamine to glutamate. GLS2 is highly expressed in postnatal liver and brain tissues and expressed at a low level in other tissues (12, 13). In cells, glutamate can be further converted into α-ketoglutarate, which is an important substrate for the citric acid cycle (TCA) to produce ATP in mitochondria. Furthermore, glutamate is a precursor of reduced GSH, one of the most important antioxidant molecules and a scavenger for ROS (8). Our finding that GLS2 could be a potential p53 target gene suggested to be a key contributor to tumorigenesis (6, 7). Considering the importance of p53 in tumor suppression, these findings suggest that p53 mutations could be a genetic change that contributes to the Warburg effect in tumors, which provides a unique mechanism for p53 in tumor suppression.

Organisms living in aerobic conditions are constantly subjected to reactive oxygen species (ROS). Increased ROS levels contribute to genetic instability and cancer initiation and progression (5, 8). Recent studies revealed a unique function for p53 in regulating cellular antioxidant defense mechanisms. p53 promotes the expression of several antioxidant proteins to decrease intracellular ROS levels, including sestrins, TIGAR, GPX1, and ALDH4 (5, 9–11). The antioxidant role of p53 is important to reduce oxidative stress-induced DNA damage and mutations, which contributes greatly to the tumor suppression activity of p53 (5).

Here, we identify human glutaminase 2 (GLS2) as a unique p53 target gene to mediate the role of p53 in both cellular energy metabolism and antioxidant defense mechanisms. The GLS2 gene encodes a mitochondrial glutaminase that catalyzes the hydrolysis of glutamine to glutamate (12, 13). p53 increases GLS2 expression under both nonstressed and stressed conditions, which results in enhanced mitochondrial respiration and ATP generation and, furthermore, increased glutathione (GSH) levels and decreased ROS levels in cells. These results suggest that GLS2 is an important component in mediating the tumor-suppressive effects of p53.

The antioxidant role of p53 is important to reduce oxidative stress-induced DNA damage and mutations, which contributes greatly to the tumor suppression activity of p53 (5).


The authors declare no conflict of interest.

See Commentary on page 7117.

†To whom correspondence may be addressed. E-mail: alevine@ias.edu or fengzh@umdnj.edu.

This article contains supporting information online at www.pnas.org/cgi/content/full/1001006107/DCSupplemental.
suggests that GLS2 may mediate p53’s function in the regulation of energy metabolism and antioxidant defense in cells.

To verify that p53 binds to these putative p53 consensus binding elements in the human GLS2 gene, three pairs of primers were designed. The V138/H1299 cells were treated with 32 °C or 37 °C. As shown in Fig. 1B, the p53 antibody specifically pulled down the DNA fragment containing the potential p53-binding element in the GLS2 promoter region. The p53-null H1299 and HCT116 p53−/− cells were cotransfected with the luciferase reporter vectors and vectors expressing either wild-type (pRC p53) or mutant p53 protein (pRC 273H) 24 h before measuring luciferase activities.

p53 induces GLS2 expression under stressed and nonstressed conditions. To investigate whether p53 regulates the expression of GLS2 under stressed and nonstressed conditions, V138/H1299 cells were treated with 32 °C or 37 °C. As shown in Fig. 1B, the p53 antibody specifically pulled down the DNA fragment containing the potential p53-binding element in the GLS2 promoter region. The p53-null H1299 and HCT116 p53−/− cells were cotransfected with the luciferase reporter vectors and vectors expressing either wild-type (pRC p53) or mutant p53 protein (pRC 273H) 24 h before measuring luciferase activities. GLS2 expression greatly increased the intracellular levels of glutamine to glutamate, exogenous GLS2 catalyze the hydrolysis of glutamine to glutamate, exogenous GLS2 was overexpressed by transfection of GLS2 expression vector with a C-terminal Flag tag (Fig. 2B, panel 1). The GLS2 antibody did not detect the endogenous GLS2 protein in the whole cell extracts of many cell lines, including lung H460 and brain HTB-15 cells. These results suggest an important role of p53 in maintaining the normal expression and function of GLS2 under nonstressed conditions.

GLS2 increases mitochondrial oxidative phosphorylation and ATP generation. To investigate how GLS2 regulates energy metabolism, GLS2 was overexpressed by transfection of GLS2 expression vector with a C-terminal Flag tag or knocked down by GLS2 siRNA oligo (Fig. 2B, panel 1). GLS2 knockdown by GLS2 siRNA oligo (≥80% knockdown as detected by real-time PCR) clearly reduced the intracellular levels of ATP.

GLS2 is a unique p53 target gene: p53 activation by various stress signals can induce GLS2 expression in various cells.
of glutamate in cells compared with control cells transfected with a scrambled siRNA oligo (Fig. 3B Right). Similar results were observed in other cells we tested. We further measured the α-ketoglutarate levels in cells. As shown in Fig. 3C, exogenous GLS2 expression increased the intracellular levels of α-ketoglutarate by ~2-fold in cells, whereas GLS2 knockdown clearly decreased the α-ketoglutarate levels. Significantly higher levels of glutamate and α-ketoglutarate were observed in HCT116 p53+/+ compared with HCT116 p53−/− cells and in LN-2024 cells after p53 protein expression (Fig. 3D and E) (P < 0.05).

The role of GLS2 in mitochondrial respiration was further investigated. Exogenous GLS2 expression clearly increased the oxygen consumption and ATP levels, whereas GLS2 knockdown clearly decreased oxygen consumption and ATP levels (Fig. 4A–E). Furthermore, glutamine depletion from media abolished the increased effect of GLS2 on ATP generation, suggesting that the enhanced glutamine metabolism is mainly responsible for the increase in ATP generation by GLS2 in cells. Interestingly, whereas enhanced glutamine metabolism is mainly responsible for the increased effect of GLS2 on ATP generation, suggesting that the enhanced glutamine metabolism is mainly responsible for this effect. Our results further show that GLS2 expression regulates intracellular NADH production. GLS2 overexpression significantly increased the NADH levels, whereas GLS2 knockdown decreased NADH levels in cells (P < 0.05) (Fig. 5C). NADH is both the primary cofactor that drives reduction and oxidation reactions and an important antioxidant. A possible mechanism accounting for this is that GLS2 accelerates the TCA cycle, which in turn produces more NADH in cells. Consistent with these findings, significantly higher GSH levels, GSH/GSSG ratio, and NADH levels were observed in HCT116 p53−/− as compared with HCT116 p53+/+ cells and in LN2024 cells treated with Dox as compared with control LN2024 cells (Fig. 5D; P < 0.05).

The ROS levels were measured in cells untreated (nonstressed) or treated with H2O2 to induce oxidative stress. Exogenous GLS2 expression clearly reduced intracellular ROS levels in both cells, whereas GLS2 knockdown by siRNA oligo resulted in a clear increase of ROS levels in both cells (Fig. 6A and B). Significantly lower ROS levels were observed in HCT116 p53+/+ cells compared with HCT116 p53−/− cells and in LN-2024 cells treated with Dox compared with untreated cells (Fig. 6C).

To further investigate whether GLS2 can protect cells from oxidative stress-induced apoptosis, cells with exogenous GLS2 expression or GLS2 knockdown were treated with H2O2 and apoptosis was measured. Exogenous GLS2 expression significantly

**GLS2 Expression Increases Cellular Antioxidant Function.** Glutamate is a precursor of GSH, a most important antioxidant molecule and a scavenger for ROS. As electrons are lost, the GSH becomes oxidized and forms oxidized glutathione (GSSG). GSH/GSSG balance reflects the redox state of cells (8). Interestingly, exogenous GLS2 expression significantly increased GSH levels and the GSH/GSSG ratio, whereas GLS2 knockdown decreased GSH levels and the GSH/GSSG ratio in cells (Fig. 5A and B) (P < 0.05). Glutamine depletion from media abolished the increased effect of GLS2 on GSH levels and GSH/GSSG ratio, suggesting that the enhanced glutamine metabolism is mainly responsible for this effect. 

**Fig. 2.** p53 increases GLS2 transcription under both stressed and nonstressed conditions. p53 induces GLS2 expression at mRNA (A) and protein levels (B) in V138/H1299 cells at 32 °C and in LN-2024 cells treated with Dox for different hours. The GLS2 mRNA levels were determined by real-time PCR and normalized with Actin. Exogenous GLS2 protein was detected using whole cell extracts from cells transfected with GLS2 expression vectors (B, panel 1). Endogenous GLS2 protein was detected using mitochondrial extracts (B, panels 2–4). GLS2 siRNA oligo was employed to knock down endogenous GLS2 expression in HepG2 cells (B, panel 2). NS: nonspecific band. (C and D) IR (10 Gy) induces GLS2 mRNA levels in a p53-dependent fashion in HCT116 and HepG2 cells. (E) Etoposide (20 μM) and H2O2 (150 μM) induce GLS2 mRNA levels in a p53-dependent fashion in HCT116 cells. (F) p53 regulates GLS2 basal expression levels.

Hu et al.
levels (α-greatly to p53 demonstrate an important role of GLS2 in antioxidant defense in apoptosis (pro-tein in cells transfected with GLS2 expression vectors. Mitochondria were function of cells in tumor suppression, our maintaining proper energy metabolism and antioxidant defense of p53 and its pathway in tumor suppression and the importance of

Reduced H2O2-induced apoptosis, whereas the GLS2 knockdown by siRNA oligo significantly sensitized cells to H2O2-induced apoptosis (P < 0.05) (Fig. 6 D and E). These results together demonstrate an important role of GLS2 in antioxidant defense in cells, suggesting that as a unique p53 target gene, GLS2 contributes greatly to p53’s role in antioxidant defense.

Loss of GLS2 Expression in Liver Tumors. Considering the critical role of p53 and its pathway in tumor suppression and the importance of maintaining proper energy metabolism and antioxidant defense function of cells in tumor suppression, our finding that GLS2 is a unique p53 target gene that mediates a portion of p53’s functions in energy metabolism and antioxidant defense suggests a potential role of GLS2 in tumor suppression. It is known that GLS2 is highly expressed in adult liver tissues. Our data show that the mRNA expression of GLS2 is almost absent or significantly decreased in all 26 specimens from hepatocellular carcinoma (HCC) at different stages that we analyzed (Origene Technologies) compared with adjacent normal liver tissues (n = 8) or tissues with cirrhosis, fatty changes, or chronic hepatitis (n = 13) as measured by real-time PCR. The expression levels of GLS2 mRNA were significantly lower in HCC compared to normal adjacent liver tissue (P < 0.0001), but not significantly different from normal liver tissues and liver tissues with cirrhosis, fatty changes, or chronic hepatitis (P = 0.23) (Fig. 7A). These results suggest that loss of GLS2 expression could be a specific event and tumor biomarker for HCC, which may contribute to liver tumorigenesis. It is well documented that ~40–50% of HCC contains DNA mutations in the p53 gene. Our data show that almost all of these HCC tissues we studied have significantly lower GLS2 expression, which suggests that there should be some other factors leading to the down-regulation of GLS2 expression in HCC in addition to p53 mutations.

Fig. 3. GLS2 expression increases the levels of intracellular glutamate and α-ketoglutarate. (A) The mitochondrial localization of exogenous GLS2 protein in cells transfected with GLS2 expression vectors. Mitochondria were stained with MitoTracker. (B) Exogenous GLS2 expression increases glutamate levels (Left), whereas GLS2 knockdown by siRNA (GLS2-siRNA) decreases glutamate levels in cells (Right) (P < 0.05). Glutamate levels were determined at 24 h after transfection. (C) (Left) Exogenous GLS2 expression increases α-ketoglutarate levels. (Right) GLS2 knockdown decreases α-ketoglutarate levels (P < 0.05). (D) and (E) p53 increases the levels of glutamate and α-ketoglutarate in cells (P < 0.05).
GLS2 Overexpression Reduces Tumor Cell Colony Formation Abilities.

To further investigate the potential role of GLS2 in tumor suppression, tumor cells, including H1299, HepG2, and HTB15 cells, were transfected with GLS2 expression vectors, and the cell colony formation ability was examined under the selection of G418. Compared with control cells transfected with empty vectors, tumor cells transfected with GLS2 expression vectors showed significantly decreased colony formation ability (up to 3- to 4-fold, P < 0.05) (Fig. 7B). These data suggest that GLS2 may play a role in tumor suppression.

Discussion

The recent identification of SCO2 and TIGAR as two p53 target genes revealed p53’s role in enhancing mitochondrial respiration and inhibiting glycolysis (3, 4). Here, we identified GLS2 as a unique p53 target gene involved in energy metabolism. The induction of GLS2 increases intracellular levels of glutamate and α-ketoglutarate and leads to the enhanced oxygen consumption, mitochondrial respiration, and ATP generation in cells. Through the regulation of GLS2, p53 increases the reliance upon glutamine metabolism, the production of glutamate and α-ketoglutarate, and mitochondrial respiration. Compared with p53-deficient cells, p53 wild-type cells have higher intracellular levels of glutamate and α-ketoglutarate, higher oxygen consumption, and higher rates of mitochondrial respiration, which are consistent with the effects of increased GLS2 expression in cells. These results demonstrated that the regulation of GLS2 and glutamine metabolism is a unique mechanism for p53 to regulate energy metabolism: restoring cells to a greater dependence upon oxidative phosphorylation.

p53 has been reported to modulate up cellular antioxidant defense mechanisms, especially under conditions of no stress or low stress, and this antioxidant activity plays an important role in the overall tumor suppressor function of p53 (5). Here, p53 promotes the expression of several antioxidant proteins that function to lower ROS levels, including sestrins, TIGAR, GPX1, and ALDH4. Sestrins are a family of proteins required for regeneration of peroxidized, the major reducers of endogenously produced peroxides in cells (9). TIGAR diverts glucose through the pentose phosphate pathway to lower ROS levels (4). ALDH4 is a mitochondrial NAD+-dependent enzyme that catalyzes the proline degradation pathway to lower ROS levels (11). GPX1 is a primary antioxidant enzyme that scavenges hydrogen peroxide or organic hydroperoxides in cells (10). The identification of GLS2 as a p53-regulated gene that functions to lower ROS levels provides further direct evidence to support the important role of p53 in antioxidant defense in cells. GLS2 increases GSH levels and reduces ROS levels in cells through increasing the levels of glutamate, a precursor of GSH. Furthermore, GLS2 increases the NADH levels. These effects contribute to GLS2’s function in lowering ROS levels in cells and thus protect cells from oxidative stress (H2O2)-induced cell death. These findings presented here not only provide further strong evidence that p53 plays an important role in cellular antioxidant defense, but also provide a unique mechanism for

Fig. 7. Loss of GLS2 expression in hepatocellular carcinomas and the inhibition of colony formation by GLS2 in tumor cells. (A) Loss or significant decrease of mRNA expression of GLS2 in human hepatocellular carcinomas. HCC, hepatocellular carcinoma; N, normal liver. Tumor adjacent tissues: L1–5, tissues with cirrhosis; L6–10, tissues with fatty changes; L11–13, tissues with chronic hepatitis. The GLS2 expression was detected by real-time PCR and normalized with Actin. GLS2 levels of N1 are designated as 1. Samples were provided by Origene Technologies. P < 0.0001 (normal vs. tumor), P < 0.0001 (normal vs. tumor), P < 0.0001 (tumor adjacent tissues vs. tumor), and P = 0.2367 (normal vs. tumor adjacent tissue). (B) Exogenous GLS2 expression reduces cell colony formation in tumor cells, including H1299, HepG2, and HTB15 cells (P < 0.05).
p53 in the regulation of antioxidant defense mechanisms through regulating glutamine metabolism and GSH production.

Our results that GLS2 levels were significantly decreased in HCC and that overexpression of GLS2 in tumor cells, including HCC cells, significantly reduced tumor cell colony formation strongly suggest a potential role of GLS2 in tumor cell growth suppression. It is known that GLS2 is expressed only in postnatal liver but not in fetal liver (12). Fetal liver, like cancer cells, use glycolysis to generate ATP and precursors for cell division. GLS2 promotes oxidative phosphorylation and the efficient use of glucose to produce ATP. Therefore, loss of GLS2 expression in HCC suggests that liver tumor cells return to a fetal-like metabolic phenotype after neoplastic transformation. Consistent with our findings, it was recently reported that GLS2 expression is lost in many brain tumors, including highly malignant glioblastomas and anaplastic astrocytomas, and restoration of GLS2 expression in glioblastoma cells inhibited tumor cell proliferation and migration (20). Brain is one of several tissues where GLS2 is highly expressed. These data together strongly suggest a potential role of GLS2 in tumor suppression. Interestingly, the GLS1 gene located in 2q32 shares a considerable degree of sequence similarity with GLS2 and encodes a kidney-type glutaminase isoform (~70 kDa). The oncogene Myc was reported to increase GLS1 expression and promote tumor cell proliferation in human P-F93 B lymphoma and PC3 prostate cancer cells (21). It appears that GLS1 and GLS2 may have contrasting roles in tumorigenesis. Several possible mechanisms may account for this: (i) The expression of GLS1 and GLS2 is regulated by different mechanisms in cells under different circumstances. For example, p53 induces the expression of GLS2 but not GLS1 as we observed in various cells. Myc induces the expression of GLS1 but not GLS2 (21). (ii) GLS1 and GLS2 have different kinetic, immunologic, and molecular characteristics. GLS1 is activated by high phosphate levels and strongly inhibited by the end-product glutamate, whereas GLS2 is activated by low phosphate levels and not inhibited by glutamate (13). Therefore, these two glutaminase isoforms may have different impacts upon the fine regulation of energy metabolism and antioxidant defense. (iii) GLS2 has been reported to interact with other proteins through the PDZ domain in its C terminus (22). GLS2 may exert its anti-tumorigenic effect through its interaction with other PDZ domain-containing proteins; and further, (iv) GLS2 overexpression in cells results in altered expression of genes, suggesting that GLS2 may act indirectly or directly as a transcription factor (20). Further studies are required to address the quite different roles and mechanisms for GLS1 and GLS2 in tumorigenesis.

In summary, we identified glutaminase 2 as a unique p53 target gene. GLS2 increases mitochondrial respiration and ATP generation. Furthermore, GLS2 increases cellular levels of GSH and NADH and decreases ROS levels in cells. Our results demonstrate that GLS2 is an important component in mediating these two unique functions of p53 in the regulation of energy metabolism and antioxidant defense.

Materials and Methods
Luciferase Activity Assay and ChIP Assay. pGL2 luciferase reporter (Promega) was used to construct luciferase reporter containing putative p53-binding elements in the GLS2 gene. Luciferase activity assays were performed as previously described (16, 23). ChIP assays were performed as previously described (16, 23).

Western-Blot Analysis and Immunofluorescence Staining. Rabbit polyclonal antibody to GLS2 was raised against a 15-aa peptide corresponding to the GLS2 human protein (PFAKDRWGNIP LDDC) (Genescript). For detection of endogenous GLS2 protein by Western blot, mitochondria were isolated and mitochondria extracts were used. Exogenous GLS2 protein was stained with anti-Flag (M2, Sigma). For MitoTracker staining, cells were incubated in MitoTracker for 30 min before fixation.

Cellular Apoptosis and Cell Colony Formation Assays. Apoptosis was measured in a flow cytometry assay as previously described (24). Colony formation assays were performed as previously described (25).

Measurement of Parameters of Energy Metabolism. Glutamate levels were measured by using the Amplex Red Glutamine Acid/Glutamate oxidase assay kit (Invitrogen). α-Ketoglutarate levels were measured by using the α-ketoglutarate assay kit (Biovision). ATP levels were measured by using the ATP Bio-luminescence assay kit (Roche). ROS levels were measured by dihydrodorahdine 123 staining in a flow cytometry assay as described (4). Oxygen consumption in cells was measured by using the BD Oxygen Biosensor System. See SI Materials and Methods for details.

Acknowledgments. This work was supported by National Institutes of Health Grant CA143204-01 (to Z.F.), by National Institutes of Health Grant P01 CA 87497 (to A.L.), and by a University of Medicine and Dentistry of New Jersey Foundation grant (to Z.F.). C.Z. was supported by a New Jersey Cancer Center Research postdoctoral fellowship.

Supporting Information

Hu et al. 10.1073/pnas.1001006107

SI Materials and Methods

Cells and Cell Transfection. Human lung H460 and H1299, liver HepG2, and brain HTB-15 cells were obtained from American Type Culture Collection. Human colon HCT116 p53+/+ and HCT116 p53−/− cells were a generous gift from B. Vogelstein at Johns Hopkins University. V138/H1299 cells were a generous gift from J. Chen at H. Lee Moffitt Cancer Center. LN-2024 cells were a generous gift from E. Van Meir at Emory University. The siRNA ology against GLS2 and p53 (Ambion) was transfected into cells using Oligofectamine 2000 (Invitrogen) according to the manufacturer’s protocol. Plasmids were transfected into cells using Lipofectamine 2000 (Invitrogen).

Chromatin Immunoprecipitation Assay. Chromatin immunoprecipitation (ChIP) assays were performed using the Upstate ChIP Assay Kit according to the manufacturer’s instructions. Primer sets were designed to encompass the potential p53-binding elements in the human GLS2 gene. The sequences are as follows: for promoter, 5′-GGCCTCTCCAAATCCAGGTTCA-3′ and 5′-TGTTTTTCTGGTGGTTTCTC-3′; for potential binding element A in intron 1, 5′-CCCCAGAAGCCAGGAAACT-3′ and 5′-TGCGCAACAGCCCGACT-3′; and for potential binding element B in intron 1, 5′-CTTTGTGTCAGGCAGT-3′; and for potential binding element C in intron 2, 5′-AATCCACCTTCCTCCTTCC-3′. The p53-binding element in the human MDM2 promoter region was used as a positive control for ChIP assays. The primers are as follows: 5′-GGTGTAGTCAGGTTTCCCTCTTG-3′ and 5′-GGAAATGCTAGTTTATAAGCC-3′.

Construction of Plasmids. For construction of GLS2 expression vector to express GLS2 protein with C-terminal Flag tag, human full-length GLS2 cDNA was generated by RT-PCR and inserted into p3xFlag-CMV-14 plasmid (Sigma) at HindIII and EcoRI sites. The primers used for PCR are as follows: 5′-AAGCTTGGCATGCCGCCTCGAAGC-3′ and 5′-TGATACGCTACGTCTCTACCTG-3′.

Luciferase Activity Assay. The pGL2 reporter plasmids containing one copy of each putative p53-binding element in the human GLS2 gene were transfected into p53 null H1299 and HCT116 p53−/− cells by using Lipofectamine 2000 (Invitrogen) along with 1 μg of pRC-wtp53 (wild-type human p53 expression plasmid) or pRC-273H (mutant human p53 expression plasmid containing a substitution at R273H) and 0.5 ng of pRL-SV40 plasmid expressing renilla luciferase as an internal control to normalize transfection efficiency. The luciferase activity was measured 20 h after transfection. The reporter activity was calculated as luciferase activity of reporter plasmids in cells with wild-type p53 compared with that in cells with mutant p53.

Quantitative Real-Time PCR. Total RNA was prepared with the RNeasy kit (Qiagen) and treated with DNase I to remove residual genomic DNA. The cDNA was prepared with random primers using the TaqMan reverse transcription kit (Applied Biosystems). Real-time PCR was done in triplicate with TaqMan PCR mixture (Applied Biosystems). The expression of genes was normalized to the Actin gene.

Western-Blot Analysis. Rabbit polyclonal antibody to GLS2 was raised against a 15-aa peptide corresponding to the GLS2 human protein (PFVADRWGNIPLD DC) (Genescript). Antibodies against p53 and DO-1 were purchased from Santa Cruz Biotechnology. Antibodies against Actin (A5441) and Flag (M2) (Sigma) were purchased from Sigma. For detection of endogeneous GLS2 protein, mitochondrial protein was enriched. Mitochondria were isolated from cells by using mitochondrial isolation kits (Qiagen) according to manufacturer’s instructions. The isolated mitochondria were lysated in RIPA buffer for the detection of GLS2 protein by Western-blot assays. For the detection of other proteins, whole cell lysates were prepared using RIPA buffer. Protein samples were separated by 4–20% SDS/PAGE and transferred to PVDF membranes. The protein levels were quantified by digitalization of the x-ray film and analyzed with Scion Image software (Scion Corporation).

Immunofluorescence Staining. Cells grown on slides were fixed with 3% paraformaldehyde for 45 min and then treated with 0.5% Triton X-100 for 5 min, blocked with 1% bovine serum albumin for 1 h, and stained with anti-Flag (M2; Sigma) to detect Flag-tagged GLS2. Slides were washed and then incubated with fluorescein isothiocyanate-conjugated secondary antibody against mouse immunoglobulin G (Molecular Probes). Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI; Sigma). For MitoTracker (Molecular Probes) staining, cells were incubated in 50 nm MitoTracker for 30 min and then fixed with paraformaldehyde.

Measurement of Intracellular Levels of Glutamate, α-Ketoglutarate, and ATP. Intracellular glutamate levels were measured by using the Amplex Red Glutamate Acid/Glutamate oxidase assay kit (Invitrogen) according to manufacturer’s instructions. Intracellular α-ketoglutarate levels were measured by using the α-ketoglutarate assay kit (Biovision), and intracellular ATP levels were measured by using the ATP Bioluminescence assay kit (Roche).

Measurement of Levels of ROS. Cells were treated with or without H2O2 (100–600 μM) for 4 h. After treatment cells were trypsinized and resuspended in PBS. Cells (1 × 106) were then incubated with 3 mM dihydrorhodamine 123 (Sigma) in PBS for 30 min at 37 °C. Cells were washed with PBS and then applied to a flow cytometer for measuring ROS levels.

Measurement of Levels of Glutathione and NADH. The levels of reduced glutathione (GSH) and oxidized glutathione (GSSG) were measured by using a glutathione detection kit (Biovision) according to manufacturer’s instructions. In brief, cell lysates were prepared using Assay Buffer (Biovision). After centrifugation, supernatants were assayed for reduced glutathione by adding o-phthalaldehyde to react only with reduced glutathione and generate fluorescence. For GSSG, a reducing agent was added to convert GSSG to GSH. Fluorescence intensities were monitored using an excitation wavelength of 340 nm and emission wavelength of 420 nm. NADH levels were measured by using an NAD+/NADH quantification kit (Biovision) according to manufacturer’s instructions.

Measurement of Oxygen Consumption. Oxygen consumption in cells was measured by using the BD Oxygen Biosensor System according to manufacturer’s instructions. This system is an oxygen-sensitive fluorescent compound embedded in a gas-permeable and hydrophobic matrix attached to the bottom of a multiwell plate. The
amount of fluorescence correlates directly to the rate of oxygen consumption in the well. In brief, cells were seeded in a 96-well plate covered with microcarrier beads (Cytodex-3; Sigma), for cells to attach better. Oxygen consumption was measured by a fluorescence plate reader using \(Ex/Em = 485/630 \text{ nm} \) at different hours after cell seeding.